Journal
NATURE BIOTECHNOLOGY
Volume 33, Issue 7, Pages 733-735Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.3212
Keywords
-
Categories
Ask authors/readers for more resources
The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-to-antibody ratio (DAR); however, ADC plasma clearance also increases with DAR, reducing exposure and in vivo efficacy. Here we show that accelerated clearance arises from ADC hydrophobicity, which can be modulated through drug-linker design. We exemplify this using hydrophilic auristatin drug linkers and PEGylated ADCs that yield uniform, high-DAR ADCs with superior in vivo performance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available